Sabby Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Sabby Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-33	Closed	-$659K	–	367
2015 Q4	$659K	Hold	33	–	–	0.04%	218
2015 Q3	$472K	Hold	33	–	–	0.02%	297
2015 Q2	$691K	Buy	+33	New	+$8.09K	0.03%	242

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Sabby Management's BLCM Position: Q1 2021 in Review

Sabby Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2021, closing a stake of 159,500 shares — an estimated $563K sold.

Sabby Management first reported a position in BLCM in Q4 2014 and held it in 9 quarters. The position peaked at $5.36M in Q1 2015. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2021.

Sabby Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 159,500 Bellicum Pharmaceuticals, Inc. shares in Q1 2021, an estimated $563K.
Sabby Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
Sabby Management's Bellicum Pharmaceuticals, Inc. position peaked at $5.36M in Q1 2015.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.